Infammasomes provide a therapeutic target against human diseases

POINT’s assumed shareholders believe that the proposed acquisition undervalues the company’s worth. Credit: Roman Samborskyi/Shutterstock.com Eli Lilly has substantiated its desire to acquire radiopharmaceutical company

The FDA re­ject­ed Zealand Phar­ma’s glucagon re­cep­tor ag­o­nist in con­gen­i­tal hy­per­in­sulin­ism (CHI) af­ter iden­ti­fy­ing prob­lems at a third-par­ty man­u­fac­tur­ing site. The com­pa­ny said it re­mains